-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Yousif Capital Management LLC Sells 29 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Yousif Capital Management LLC Sells 29 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Yousif Capital Management LLC decreased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 1.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,769 shares of the medical research company's stock after selling 29 shares during the period. Yousif Capital Management LLC's holdings in Bio-Rad Laboratories were worth $1,155,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. SeaCrest Wealth Management LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter worth $26,000. Private Trust Co. NA grew its position in Bio-Rad Laboratories by 230.0% in the third quarter. Private Trust Co. NA now owns 66 shares of the medical research company's stock valued at $28,000 after purchasing an additional 46 shares in the last quarter. Atlas Capital Advisors LLC bought a new position in Bio-Rad Laboratories in the second quarter valued at $50,000. Allworth Financial LP grew its position in Bio-Rad Laboratories by 414.8% in the third quarter. Allworth Financial LP now owns 139 shares of the medical research company's stock valued at $58,000 after purchasing an additional 112 shares in the last quarter. Finally, Sentry Investment Management LLC grew its position in Bio-Rad Laboratories by 16.5% in the second quarter. Sentry Investment Management LLC now owns 148 shares of the medical research company's stock valued at $73,000 after purchasing an additional 21 shares in the last quarter. Institutional investors own 64.35% of the company's stock.
Get Bio-Rad Laboratories alerts:Bio-Rad Laboratories Stock Performance
Shares of BIO stock opened at $470.88 on Friday. The stock has a market cap of $14.04 billion, a P/E ratio of -2.33 and a beta of 0.92. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.50 and a quick ratio of 4.30. The company has a fifty day moving average price of $432.84 and a two-hundred day moving average price of $447.07. Bio-Rad Laboratories, Inc. has a one year low of $344.63 and a one year high of $670.61.
Analyst Upgrades and Downgrades
BIO has been the subject of a number of analyst reports. TheStreet downgraded shares of Bio-Rad Laboratories from a "c" rating to a "d+" rating in a research report on Thursday, October 27th. Royal Bank of Canada assumed coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, December 6th. They issued an "outperform" rating and a $565.00 target price for the company. Credit Suisse Group cut their price target on shares of Bio-Rad Laboratories from $715.00 to $640.00 and set an "outperform" rating for the company in a research note on Friday, October 28th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, January 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $651.25.Bio-Rad Laboratories Company Profile
(Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
See Also
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
根据Yousif Capital Management LLC最近提交给美国证券交易委员会(Securities&Exchange Commission)的Form 13F文件，该公司在第三季度减持了Bio-Rad实验室公司(NYSE：BioGet Rating)的股份1.0%。在此期间，该机构投资者出售了29股，持有这家医疗研究公司2,769股股票。截至最近一个季度末，Yousif Capital Management LLC持有的Bio-Rad实验室股份价值1,155,000美元。
其他大型投资者最近也对他们在该公司的头寸进行了调整。Seacrest Wealth Management LLC在第二季度购买了Bio-Rad实验室价值2.6万美元的新股。私人信托公司NA第三季度在Bio-Rad实验室的头寸增加了230.0%。私人信托公司NA现在拥有66股这家医疗研究公司的股票，价值28,000美元，在上个季度又购买了46股。Atlas Capital Advisors LLC在第二季度以5万美元的价格收购了Bio-Rad实验室的一个新头寸。Allworth Financial LP在第三季度将其在Bio-Rad实验室的头寸增加了414.8%。Allworth Financial LP现在拥有139股这家医疗研究公司的股票，价值5.8万美元，上个季度又购买了112股。最后，Sentry Investment Management LLC在第二季度将其在Bio-Rad实验室的头寸增加了16.5%。在上个季度又购买了21股股票后，哨兵投资管理公司现在拥有148股这家医疗研究公司的股票，价值7.3万美元。机构投资者持有该公司64.35%的股份。
到达Bio-Rad实验室警报：Bio-Rad实验室股票表现
上周五，Bio股票开盘报470.88美元。该股市值为140.4亿美元，市盈率为-2.33，贝塔系数为0.92。该公司的债务权益比为0.14，流动比率为5.50，速动比率为4.30。该公司的50日移动平均价为432.84美元，200日移动平均价为447.07美元。Bio-Rad实验室公司的一年低点为344.63美元，一年高位为670.61美元。
分析师升级和下调评级
BIO已经成为了许多分析师报告的主题。华尔街在10月27日星期四的一份研究报告中将Bio-Rad实验室的股票评级从“c”下调至“d+”。加拿大皇家银行在12月6日(星期二)的一份研究报告中承担了对Bio-Rad实验室股票的报道。他们对该公司的评级为“跑赢大盘”，目标价为565.00美元。瑞士信贷集团将Bio-Rad实验室的股票目标价从715.00美元下调至640.00美元，并在10月28日星期五的一份研究报告中为该公司设定了“跑赢大盘”的评级。最后，在1月18日星期三的一份研究报告中，StockNews.com将Bio-Rad实验室的股票评级从“买入”下调至“持有”。一名分析师对该股的评级为持有，四名分析师对该公司股票的评级为买入。根据MarketBeat，该股目前的共识评级为“适度买入”，平均目标价为651.25美元.Bio-Rad实验室公司简介
(获取评级)
Bio-Rad实验室公司致力于开发和生产用于生化、制药和其他生命科学研究应用的特殊化学品。它通过生命科学和临床诊断部门开展业务。生命科学部门开发、制造和销售试剂、仪器和实验室仪器。
另请参阅
- 免费获取StockNews.com关于Bio-Rad实验室的研究报告(BIO)
- 市场回顾周-1/30-2/3
- 细价股值得吗？你应该投资细价股吗？
- Zimmer Biomet盈利节节攀升，增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
想看看其他对冲基金持有哪些传记吗？访问HoldingsChannel.com，获取Bio-Rad实验室，Inc.(纽约证券交易所：Bio-Get Rating)的最新13F文件和内幕交易。
每天收到Bio-Rad实验室的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bio-Rad实验室和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧